Non-invasive prenatal testing
Accurate, thorough and completely non-invasive
You can learn genetic information about your baby as early as nine weeks into your pregnancy using the Panorama™ Prenatal Screen.
- Screens for genetic abnormalities
- Identifies the baby’s gender
- Done via single blood test
- Non-invasive, so there is no risk to your baby
Safe and reliable
– pricing from £455
What is Panorama?
Panorama™ is a non-invasive DNA screen that can provide you with crucial information about your pregnancy. It can be carried out as early as nine weeks of gestation. With Panorama, you can find out for the likelihood of your baby having a chromosomal abnormality, such as Down syndrome, simply by providing a sample of your blood. If you desire, you can also find out the gender of your baby.
Why choose Panorama™?
- Panorama screens for conditions that other tests cannot, like molar pregnancy, vanishing twin and triploidy
- Uniquely, Panorama distinguishes between maternal and fetal DNA, reducing the chance of false positives
- Panorama has a greater than 99% accuracy rate for Down’s syndrome
- Panorama determines gender more accurately than any other NIPT
- Panorama is the most sensitive test for 22q11.2 deletion syndrome, a frequent and potentially severe microdeletion that affects women of any age
What the experts say…
Panorama is evaluated in 12 peer-reviews publications and more than 60,000 pregnancies.
Validated in high-risk and low-risk patients
“This noninvasive prenatal screen performed with high high sensitivity and specificity in high-risk and low-risk cohorts… The SNP-based method resulted in improved overall performance over quantitive methods.”
– Pergament et al. Single -nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol, Aug 2014; 124 (2PT 1):210-8. (Study of 1,064 samples, mixture of high-risk and low risk)
Screens for microdeletions with high accuracy
“SNP-based noninvasive prenatal micro deletion screening is highly accurate… for the general pregnant population should be considered.”
– Wapner et al. Expanding the scope of non-invasive prenatal testing: Detection of fatal microdeletion syndromes. Am J Obset Gynecol 2015;doi: 10.1016/j.ajog.2014.11.041. (study of 469 samples.)
What Panorama™ Screens For:
Panorama™ is the only non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera’s proprietary algorithm. Using advanced bioinformatics techniques, Panorama screens for a broad panel of chromosomal conditions, including:
- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)
Sex Chromosome Abnormalities:
- Monosomy X (Turner syndrome)
- Klinefelter syndrome
- Triple X syndrome
- XYY syndrome
- 22q11.2 deletion syndrome
- 1p36 deletion syndrome
- Prader-Willi syndrome
- Angolan syndrome
- Cri-du-chat syndrome
- Gender of the Baby (optional)
Is Panorama right for me?
According to the International Society for Prenatal Diagnosis (ISPD), non-invasive prenatal testing, including Panorama, is appropriate as a primary screening test for pregnant women of all ages. Down syndrome and certain other chromosomal conditions occur more frequently in babies born to mothers over 35 years old. Other conditions for which Panorama screens – such as microdeletion syndromes – occur with the same frequency in babies, regardless of the mother’s age.
Currently, Panorama cannot be used in the following types of pregnancies:
- Multiple gestation pregnancies
- Pregnancies that are using an egg donor or a surrogate
- Pregnant women who are bone marrow transplant recipients